Genetics, genomics, targeted therapy, and the costs of care
A new paper in a new journal argues that all men diagnosed with advanced forms of prostate cancer should now, routinely, be undergoing tumor and germline DNA profiling so as to guide enrollment into...
View ArticleHow close are we really to “precision medicine” for cancer care?
A newly published paper in the journal JCO Precision Oncology confirms what many of us may have suspected — that the practical application of somatic tissue testing to clinical decision-making was low...
View ArticleGermline genetics and different responses to different types of ADT
Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen...
View ArticleCommercially available liquid biopsy data may be misleading
A newly published research letter in JAMA Oncology is entitled “Patient-paired sample congruence between 2 commercial liquid biopsy tests”. The two tests are both said — by the companies that market...
View ArticleExperts create guidelines for screening prostate cancer patients for...
Knowing whether you carry inherited cancer risk genes can help you to make the best decisions for your treatment and for your family. The genes you inherited from your parents can play an important...
View ArticleYour genetics can accurately predict your age-related prostate cancer risk
Data from a new study reported in the British Medical Journal discusses a “polygenic hazard score” that can potentially be used to guide screening for aggressive prostate cancer (but only in men of...
View ArticleWhat did you hope to learn from your genetic test … if you have ever had one?
There’s a very nice article today on the MedPage Today web site about the medical value of “at-home genetic testing” (i.e., the sorts of tests available from companies like 23&Me and some others)....
View ArticleCureTalk with Dr. Eli Van Allen on the “Metastatic Prostate Cancer Project”
On Wednesday, February 21, at 5:00 p.m. Eastern time (2:00 p.m. Pacific), we will be collaborating with CureTalks to present the next CureTalk on prostate cancer. It will address the recently launched...
View ArticleThe Metastatic Prostate Cancer Project: listen to the program
Yesterday evening we were pleased to be able to collaborate with CureTalks to host a conversation with Dr. Eli Van Allen — the principal investigator for the Metastatic Prostate Cancer Project — to...
View ArticleWhat we need to tell sons and grandsons about their risk for prostate cancer
Over the past few years, with the increased focus on the idea of “personalized” medicine, we have become increasingly informed about and focused on correlations between genetics and genomics and risk...
View ArticleMedicare to cover genetic/genomic testing in advanced cancers
In an important decision announced late on Friday last week, the Centers for Medicare & Medicaid Services (CMS) announced that it had agreed to cover costs associated with genetic/genomic testing...
View ArticleAre genomic tests for prognostic risk at diagnosis really helpful (yet)?
One of the critical and unanswered questions about the value of genomic/genetic testing in relation to the diagnosis and prognosis of prostate cancer is, “What are the currently available tests...
View ArticleGermline mutations and risk for advanced prostate cancer
Many people are increasingly interested in whether genetic testing can help them to understand their risk for cancer. The basic answer is that “Yes, it can.” However, what is also clear is that it is...
View ArticleGermline genetic testing for men with prostate cancer
In this week’s Journal of Clinical Oncology, there is a full-text article in the “Comments and Controversies” section entitled “Germline testing for men with prostate cancer: navigating an expanding...
View ArticleGenomic data and prostate cancer risk classification: an update
Three different molecular tests have been validated as providing useful data that can help a man and his doctors to come to decisions about the management and treatment of localized prostate cancer....
View Article